

# Å<sup>1/2</sup>eljko Reiner

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4756874/publications.pdf](https://exaly.com/author-pdf/4756874/publications.pdf)

Version: 2024-02-01

208  
papers

61,833  
citations

12443

66  
h-index

1706

206  
g-index

224  
all docs

224  
docs citations

224  
times ranked

46571  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,742
2	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701	2.2	5,369
3	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,298
4	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,073
5	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	2.2	3,496
6	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.2	3,172
7	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	2.2	2,806
8	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	5.5	2,601
9	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	2.2	2,460
10	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 f gBT /Overlock 10 T	2.2	2,380
11	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.3	2,327
12	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,791
13	Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal, 2010, 31, 2844-2853.	2.2	1,450
14	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2851-2906.	2.2	1,414
15	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.8	1,235
16	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 2011, 32, 1345-1361.	2.2	1,017
17	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0 284314 0 gBT /Overdr	2.2	1,017
18	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	797

#	ARTICLE	IF	CITATIONS
19	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	1.8	609
20	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.8	565
21	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.8	417
22	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	1.5	373
23	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 38BT /Over	0.8	417
24	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. <i>Atherosclerosis</i> , 2007, 194, 1-45.	0.8	295
25	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 401-411.	13.5	272
26	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	2.2	271
27	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.8	249
28	Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction. <i>Atherosclerosis</i> , 2014, 235, 21-30.	0.8	248
29	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	5.9	246
30	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	1.9	234
31	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	1.7	229
32	Statins and the COVID-19 main protease: in silico evidence on direct interaction. <i>Archives of Medical Science</i> , 2020, 16, 490-496.	0.9	227
33	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	5.5	221
34	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.9	213
35	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 999-1008.	6.2	204
36	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 530-540.	2.8	195

#	ARTICLE	IF	CITATIONS
37	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.8	183
38	The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. <i>Frontiers in Pharmacology</i> , 2020, 11, 1300.	3.6	175
39	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2017, 33, 1-5.	2.8	172
40	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	172
41	Statins in the primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 453-464.	13.5	163
42	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 2007-2018.	1.8	155
43	Relation of Atherosclerotic Changes in Retinal Arteries to the Extent of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 1107-1109.	1.5	148
44	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , 2018, 275, 265-272.	0.8	146
45	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015, 241, 169-175.	0.8	134
46	The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Food and Function</i> , 2019, 10, 6042-6051.	4.6	130
47	Physicians'™ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey. <i>Atherosclerosis</i> , 2010, 213, 598-603.	0.8	118
48	Adverse Effects of Statins - Myths and Reality. <i>Current Pharmaceutical Design</i> , 2015, 21, 1220-1226.	1.8	112
49	Population-level changes to promote cardiovascular health. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 409-421.	1.8	108
50	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	108
51	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	6.8	106
52	Management of patients with familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2015, 12, 565-575.	13.5	101
53	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	7.1	101
54	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	1.8	95

#	ARTICLE	IF	CITATIONS
55	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. <i>Current Cardiology Reports</i> , 2012, 14, 709-720.	2.8	94
56	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.8	94
57	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.4	92
58	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1664-1678.	3.5	91
59	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	6.2	91
60	Blood pressure control and knowledge of target blood pressure in coronary patients across Europe. <i>Journal of Hypertension</i> , 2011, 29, 1641-1648.	0.5	89
61	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016, 209, 284-290.	1.6	86
62	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1354-1362.	1.8	85
63	Combined therapy in the treatment of dyslipidemia. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 19-28.	2.0	81
64	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.1	75
65	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 53-65.	7.1	72
66	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2021, 166, 105499.	7.1	71
67	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrateâ€“statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.4	67
68	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013, 231, 300-307.	0.8	66
69	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020, 158, 104891.	7.1	63
70	Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2022, 2022, 1-20.	3.0	63
71	Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. <i>European Heart Journal</i> , 2012, 33, 2865-2872.	2.2	62
72	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 1313.	2.5	61

#	ARTICLE	IF	CITATIONS
73	Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey. <i>Preventive Medicine</i> , 2010, 51, 494-496.	3.5	59
74	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 212, 160-168.	1.6	55
75	Guía de la ESC/EAS sobre el manejo de las dislipemias. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 1168.e1-1168.e60.	1.3	53
76	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2016, 76, 947-956.	10.8	51
77	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. <i>Cancer Cell International</i> , 2020, 20, 560.	4.2	46
78	Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. <i>European Heart Journal</i> , 2014, 35, 590-598.	2.2	45
79	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1202-1210.	1.8	43
80	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1383-1401.	1.8	43
81	Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients. <i>Clinical Drug Investigation</i> , 2005, 25, 701-707.	2.2	42
82	Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19. <i>International Journal for Vitamin and Nutrition Research</i> , 2022, 92, 49-66.	1.5	42
83	Step-by-step diagnosis and management of the nocebo/drug effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	7.3	42
84	Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment. <i>Plant Foods for Human Nutrition</i> , 2020, 75, 307-315.	3.2	41
85	Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9 – A Narrative Review. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-6.	2.5	40
86	The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Lipids in Health and Disease</i> , 2020, 19, 112.	3.0	39
87	Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. <i>Cancer Cell International</i> , 2021, 21, 388.	4.2	39
88	Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 3172-3184.	10.0	38
89	The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2020, 34, 239-253.	5.9	38
90	The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1879-1894.	1.8	38

#	ARTICLE	IF	CITATIONS
91	PCSK9 inhibitors “ past, present and future. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1517-1521.	3.3	37
92	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Annals of Medicine, 2018, 50, 565-575.	3.8	37
93	Management of overweight and obese patients with coronary heart disease across Europe. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 447-454.	2.8	36
94	Educational level and risk profile and risk control in patients with coronary heart disease. European Journal of Preventive Cardiology, 2016, 23, 881-890.	1.8	36
95	Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress. Journal of Cellular Physiology, 2018, 233, 2928-2936.	4.1	36
96	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology, 2021, 28, 33-43.	1.8	36
97	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 646-654.	2.8	35
98	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atherosclerosis Supplements, 2019, 39, e1-e8.	1.4	35
99	Medicinal plants and bioactive natural compounds as inhibitors of HMG-CoA reductase: A literature review. BioFactors, 2020, 46, 906-926.	5.4	35
100	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). Nutrition Research Reviews, 2020, 33, 155-179.	4.6	35
101	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. Frontiers in Cardiovascular Medicine, 2022, 9, 820260.	2.4	35
102	The perception and knowledge of cardiovascular risk factors among medical students. Croatian Medical Journal, 2012, 53, 278-284.	0.9	34
103	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. European Journal of Preventive Cardiology, 2015, 22, 1212-1219.	1.8	34
104	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. Thrombosis and Haemostasis, 2016, 116, 162-171.	3.4	34
105	PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis, 2018, 270, 187-188.	0.8	34
106	Risk stratification in cardiovascular disease primary prevention “ scoring systems, novel markers, and imaging techniques. Fundamental and Clinical Pharmacology, 2012, 26, 163-174.	2.0	33
107	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiología, 2012, 65, 938.e1-938.e59.	1.3	31
108	Cardiovascular disease (CVD) risk factors in older adults “ Perception and reality. Archives of Gerontology and Geriatrics, 2015, 61, 88-92.	3.0	31

#	ARTICLE	IF	CITATIONS
109	The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. <i>British Journal of Nutrition</i> , 2020, 123, 792-799.	2.6	31
110	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 328-339.	1.8	31
111	The burden of hyperlipidaemia and diabetes in cardiovascular diseases. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 1-3.	2.0	30
112	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , 2013, 54, 339-345.	0.9	30
113	Primary Prevention of Cardiovascular Disease with Statins in the Elderly. <i>Current Atherosclerosis Reports</i> , 2014, 16, 420.	4.7	29
114	PCSK9 and infection: A potentially useful or dangerous association?. <i>Journal of Cellular Physiology</i> , 2018, 233, 2920-2927.	4.1	28
115	The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2019, 33, 2609-2621.	5.9	28
116	The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis. <i>Biomolecules</i> , 2019, 9, 416.	4.1	28
117	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , 2019, 40, 336-344.	2.2	28
118	The effects of saffron ( <i>Crocus sativus</i> L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. <i>Complementary Therapies in Medicine</i> , 2020, 48, 102250.	2.8	28
119	Effects of statins on preeclampsia: A systematic review. <i>Pregnancy Hypertension</i> , 2021, 23, 123-130.	1.8	28
120	Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia. <i>Circulation Research</i> , 2014, 114, 233-235.	6.5	25
121	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	1.6	25
122	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. <i>Croatian Medical Journal</i> , 2011, 52, 566-575.	0.9	24
123	A review of gene- and cell-based therapies for familial hypercholesterolemia. <i>Pharmacological Research</i> , 2019, 143, 119-132.	7.1	24
124	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	5.8	24
125	Quercetin as a Novel Therapeutic Approach for Lymphoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	4.1	24
126	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , 2022, 348, 25-35.	0.8	24



#	ARTICLE	IF	CITATIONS
127	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. Revista Española De Cardiología, 2013, 66, 53.e1-53.e46.	1.3	23
128	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. European Journal of Preventive Cardiology, 2020, 27, 1630-1636.	1.8	23
129	Macrophage: A Key Therapeutic Target in Atherosclerosis?. Current Pharmaceutical Design, 2019, 25, 3165-3174.	1.8	23
130	Prevention of cardiovascular disease guided by total risk estimations – challenges and opportunities for practical implementation: highlights of a Cardiovascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy. European Journal of Preventive Cardiology, 2012, 19, 1454-1464.	1.8	22
131	Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Cardiovascular Drugs and Therapy, 2017, 31, 197-208.	2.8	22
132	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. European Journal of Preventive Cardiology, 2017, 24, 84-91.	1.8	22
133	The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN, 2020, 38, 43-49.	1.2	22
134	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. European Journal of Preventive Cardiology, 2016, 23, 1618-1627.	1.8	21
135	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. Archives of Medical Science, 2021, 17, 856-863.	0.9	21
136	Diabetic dyslipidemia or “diabetes lipidus”? Expert Review of Cardiovascular Therapy, 2011, 9, 341-348.	1.5	19
137	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2018, 12, 801-809.	1.5	19
138	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. Archives of Medical Science, 2019, 15, 1365-1374.	0.9	19
139	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. Frontiers in Pharmacology, 2021, 12, 575877.	3.6	19
140	Impact of Intravenous Trehalose Administration in Patients with Niemann-Pick Disease Types A and B. Journal of Clinical Medicine, 2022, 11, 247.	2.5	19
141	Unterschiede in den Risikofaktoren für koronare Herzkrankheit bei kroatischen Patienten von kontinentalen und mediterranen Regionen. Wiener Klinische Wochenschrift, 2008, 120, 684-692.	2.0	18
142	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	18
143	A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels. Current Medicinal Chemistry, 2016, 23, 4490-4503.	2.4	18
144	New Therapeutic Approaches in Treatment of Dyslipidaemia – A Narrative Review. Pharmaceuticals, 2022, 15, 839.	3.8	18

#	ARTICLE	IF	CITATIONS
145	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , 2018, 8, e021508.	2.1	16
146	The role of statins in lung cancer. <i>Archives of Medical Science</i> , 2021, 18, 141-152.	0.9	16
147	Impact of Bariatric Surgery on Pulse Wave Velocity as a Measure of Arterial Stiffness: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2021, 31, 4461-4469.	2.3	16
148	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	4.1	16
149	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	1.3	15
150	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. <i>Current Atherosclerosis Reports</i> , 2019, 21, 14.	4.7	15
151	Resveratrol and Cardiac Fibrosis Prevention and Treatment. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 190-200.	1.7	15
152	A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders. <i>Complementary Therapies in Medicine</i> , 2020, 53, 102507.	2.8	14
153	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. <i>International Journal of Cardiology</i> , 2021, 322, 227-232.	1.6	14
154	Novel Experimental Agents for the Treatment of Hypercholesterolemia. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 91-100.	3.3	14
155	New ESC/EAS Guidelines for the management of dyslipidaemias – any controversies behind the consensus?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 724-727.	2.8	13
156	A comparison of European and US guidelines for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 215-220.	2.8	13
157	Treatment of children with homozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1095-1097.	1.8	13
158	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, 177, 25-52.	1.9	13
159	Mutation detection in Croatian patients with Familial Hypercholesterolemia. <i>Annals of Human Genetics</i> , 2013, 77, 22-30.	0.9	12
160	The effects of omega-3 fatty acids supplementation on metabolic status in pregnant women: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1685-1699.	1.8	12
161	Statin therapy and sex hormones. <i>European Journal of Pharmacology</i> , 2021, 890, 173745.	3.5	12
162	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	3.0	12

#	ARTICLE	IF	CITATIONS
163	Clinical Study on the Effect of Simvastatin on Paraoxonase Activity. <i>Arzneimittelforschung</i> , 2007, 57, 647-653.	0.4	11
164	Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. <i>Journal of Clinical Medicine</i> , 2019, 8, 1742.	2.5	11
165	Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. <i>Angiology</i> , 2020, 71, 105-107.	1.8	11
166	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. <i>Journal of Clinical Medicine</i> , 2021, 10, 4930.	2.5	11
167	Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 24.	1.6	10
168	Guidelines, position papers and critical reviews: differences and similarities. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 3-5.	1.8	9
169	The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , 2019, 25, 3266-3281.	1.8	9
170	Preparation of MnO <sub>2</sub> Loaded Hydrothermal Carbon-coated Electrospun PAN Fiber Membranes for Highly Efficient Adsorption and Separation of Cationic Dye. <i>Chemical Research in Chinese Universities</i> , 2020, 36, 1292-1301.	2.6	8
171	Effects of Statins on Renin-“Angiotensin System. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 80.	1.6	8
172	Can we further optimize statin therapy to increase tolerability?. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 843-847.	5.1	7
173	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. <i>Journal of Hypertension</i> , 2019, 37, 2015-2023.	0.5	7
174	Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: A meta-analysis of randomized clinical trials. <i>Clinical Nutrition ESPEN</i> , 2020, 37, 24-33.	1.2	7
175	Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?. <i>Critical Reviews in Food Science and Nutrition</i> , 2021, 61, 325-336.	10.0	7
176	The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 682352.	2.4	7
177	The importance of smoking cessation in patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2018, 258, 26-27.	1.6	6
178	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. <i>Current Medicinal Chemistry</i> , 2021, 28, 6066-6081.	2.4	6
179	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018, 21, 1334-1336.	1.1	5
180	Treatment of children with heterozygous familial hypercholesterolemia. <i>International Journal of Cardiology</i> , 2020, 304, 177-178.	1.6	5

#	ARTICLE	IF	CITATIONS
181	Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102381.	2.0	5
182	Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity. <i>Arzneimittelforschung</i> , 2005, 55, 271-275.	0.4	4
183	Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de Tj ETOg1 1 0.784314 rs)	0.7	4
184	Statins for primary prevention: problems with cardiovascular-risk estimation?. <i>Nature Reviews Cardiology</i> , 2013, 10, 547-547.	13.5	4
185	The association between lipid-lowering drugs and circulating concentration of PCSK9. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 928-929.	1.8	4
186	Why might visit-to visit variability of lipoproteins have an effect on cardiovascular events?. <i>Atherosclerosis</i> , 2020, 312, 99-100.	0.8	4
187	Artisanal Fisher Knowledge and Attitudes Concerning Compressor Fishing in a North-Eastern Brazilian Marine Protected Area. <i>Human Ecology</i> , 2020, 48, 357-366.	1.5	4
188	In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). <i>Chemico-Biological Interactions</i> , 2021, 345, 109528.	4.1	4
189	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. <i>Kardiologia Polska</i> , 2015, 73, 471-477.	0.6	4
190	Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1018-1028.	1.3	4
191	Polypill is not a "vaccine-like"™ solution for primary cardiovascular disease prevention in all parts of the world. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, 981-982.	3.9	3
192	Oxidative stress mediated cytogenotoxicological effects of phytol in wistar albino rats. <i>Advances in Traditional Medicine</i> , 2023, 23, 273-290.	2.0	3
193	The effect of nuts consumption on circulating oxidized low-density lipoproteins: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2023, 37, 1678-1687.	5.9	3
194	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. <i>Clinical Lipidology</i> , 2010, 5, 325-328.	0.4	2
195	Guidelines on CVD prevention: confusing or complementary?. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 6-8.	1.8	2
196	Statins in heart failure – A failure?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 397-401.	2.6	1
197	Impact of Treating Dyslipidemia on Cardiovascular Events. , 2011, , 238-246.		1
198	The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair. <i>Heart Failure Reviews</i> , 2020, , 1.	3.9	1

#	ARTICLE	IF	CITATIONS
199	At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products. Journal of Medical Economics, 2020, 23, 1193-1195.	2.1	1
200	Differential Expression of miRNA-223 in Coronary In-Stent Restenosis. Journal of Clinical Medicine, 2022, 11, 849.	2.5	1
201	Is there any association between plasma lipid profile and severity of COVID-19?. Clinical Nutrition ESPEN, 2022, 49, 191-196.	1.2	1
202	Dietary management of patients at high risk for cardiovascular disease; EUROASPIRE V. Clinical Nutrition ESPEN, 2023, 55, 144-150.	1.2	1
203	The effect of trehalose administration on the serum expression levels of microRNAs associated with lipid metabolism and autophagy process in patients with myocardial infarction - the post-hoc analysis of the TREAT-IR trial.. Archives of Medical Science, 0, , .	0.9	1
204	Statistical vs clinical significance: A matter of debate for orlistat treatment. Pharmacological Research, 2017, 124, 158-159.	7.1	0
205	Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach. Journal of the Endocrine Society, 2021, 5, A311-A311.	0.2	0
206	The Effects of N-acetylcysteine on Inflammatory Markers and Homocysteine: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Pharmaceutical Sciences, 2020, 26, 214-224.	0.3	0
207	Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome " A case report. Transfusion and Apheresis Science, 2021, , 103346.	0.9	0
208	2024 Update on Postmarketing Nutrivigilance Safety Profile: A Line of Dietary Food Supplements Containing Red Yeast Rice for Dyslipidemia.. Archives of Medical Science, 0, , .	0.9	0